Duchenne Muscular Dystrophy  >>  Duvyzat (givinostat)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Duvyzat (givinostat) / Italfarmaco
NCT02851797 / 2016-000401-36: Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Completed
3
179
Europe, Canada, US, RoW
givinostat, ITF2357, placebo
Italfarmaco, Syneos Health
Duchenne Muscular Dystrophy
02/22
02/22
ULYSSES, NCT05933057: Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting
3
138
Europe, Canada
Givinostat, ITF2357, Placebo
Italfarmaco, Fortrea
Duchenne Muscular Dystrophy
02/28
02/28
NCT03373968 / 2017-000397-10: Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Enrolling by invitation
2/3
206
Europe, Canada, US, RoW
Givinostat
Italfarmaco, Cromsource
Duchenne Muscular Dystrophy
12/25
12/25

Download Options